AR022672A1 - Una composicion farmaceutica en forma de tabletas o capsulas que constituyen un metodo de administracion oral de una droga - Google Patents
Una composicion farmaceutica en forma de tabletas o capsulas que constituyen un metodo de administracion oral de una drogaInfo
- Publication number
- AR022672A1 AR022672A1 ARP990104682A ARP990104682A AR022672A1 AR 022672 A1 AR022672 A1 AR 022672A1 AR P990104682 A ARP990104682 A AR P990104682A AR P990104682 A ARP990104682 A AR P990104682A AR 022672 A1 AR022672 A1 AR 022672A1
- Authority
- AR
- Argentina
- Prior art keywords
- drug
- pharmaceutical composition
- tablets
- ciprofloxacin
- capsule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Una composicion farmacéutica en forma de tabletas o cápsulas proporciona una combinacion de control temporal y espacial de administracion de droga a unpaciente para lograr resultados terapéuticos efectivos. La composicion farmacéutica comprende unad roga, un componente generador de gas, un agente dilatador,un agente viscosante y, optativamente, un polímero geleficante. El agente dilatador pertenece a una clase de compuestos conocidos como superdesintegradores(por ejemplo, polivinilpirrolidonade enlace cruzado o carboximetilcelulosa sodica). El agente viscosante inicialmente y, luego, el polímero gelificante,forman una matriz de gel hidratado que atrapa el gas, haciendo que la tableta o cápsula flote de manera que quede retenida en elestom ago o en la partesuperior del intestino delgado (control espacial). Al mismo tiempo, la matriz de gel hidratado forma una trayectoria de difusion tortuosa para la droga, lo queresulta en una liberacion sostenida de la droga (control temporal).Una fo rmulacion preferida de ciprofloxacina de una sola administracion diaria comprende69,9% base de ciprofloxacina, 0,34% de alginato de sodio, 1,03% de goma xántica, 13,7% de bicarbonato de sodio, 12,1% de polivinilpirrolidona de enlace cruzadoy,optativ amente, otros excipientes farmacéuticos, estando la formulacion preparada en forma de tableta recubierta o no recubierta o de cápsula.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/152,932 US6261601B1 (en) | 1997-09-19 | 1998-09-14 | Orally administered controlled drug delivery system providing temporal and spatial control |
Publications (1)
Publication Number | Publication Date |
---|---|
AR022672A1 true AR022672A1 (es) | 2002-09-04 |
Family
ID=22545063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990104682A AR022672A1 (es) | 1998-09-14 | 1999-09-17 | Una composicion farmaceutica en forma de tabletas o capsulas que constituyen un metodo de administracion oral de una droga |
Country Status (41)
Country | Link |
---|---|
EP (2) | EP1107741B1 (es) |
JP (1) | JP2002524494A (es) |
CN (1) | CN1186013C (es) |
AP (1) | AP1659A (es) |
AR (1) | AR022672A1 (es) |
AT (1) | ATE245414T1 (es) |
AU (1) | AU758324B2 (es) |
BG (1) | BG105339A (es) |
BR (1) | BR9913696A (es) |
CA (1) | CA2343760A1 (es) |
CO (1) | CO5130022A1 (es) |
CU (1) | CU23040A3 (es) |
CZ (1) | CZ2001901A3 (es) |
DE (1) | DE69909801T2 (es) |
DK (1) | DK1107741T3 (es) |
EA (2) | EA005767B1 (es) |
EE (1) | EE200100153A (es) |
ES (1) | ES2204098T3 (es) |
GE (1) | GEP20043216B (es) |
HK (1) | HK1037967A1 (es) |
HR (1) | HRP20010187B1 (es) |
HU (1) | HUP0103632A3 (es) |
ID (1) | ID29843A (es) |
IL (1) | IL141977A0 (es) |
IS (1) | IS5885A (es) |
MX (1) | MXPA01002634A (es) |
MY (1) | MY127952A (es) |
NO (1) | NO20011276L (es) |
NZ (2) | NZ523747A (es) |
OA (1) | OA11652A (es) |
PE (1) | PE20001058A1 (es) |
PL (1) | PL346798A1 (es) |
PT (1) | PT1107741E (es) |
SI (1) | SI1107741T1 (es) |
SK (1) | SK285478B6 (es) |
SV (1) | SV1999000152A (es) |
TR (1) | TR200100731T2 (es) |
UA (1) | UA73287C2 (es) |
UY (1) | UY25710A1 (es) |
WO (1) | WO2000015198A1 (es) |
ZA (1) | ZA995839B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
OA12381A (en) * | 2000-03-03 | 2004-09-06 | Ranbaxy Lab Ltd | Orally administered controlled delivery system foronce daily administration of ciprofloxacin. |
DE10031043A1 (de) | 2000-06-26 | 2002-02-14 | Bayer Ag | Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung |
AU2006202275A1 (en) * | 2000-06-26 | 2006-06-22 | Bayer Healthcare Ag | Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
MXPA03001206A (es) | 2000-08-08 | 2003-06-30 | Daiichi Pharmaceutical Co Ltd | Preparacion solida altamente absorbible. |
IN192748B (es) * | 2000-08-29 | 2004-05-15 | Ranbaxy Lab Ltd | |
WO2002045695A2 (en) | 2000-12-05 | 2002-06-13 | Alexander Macgregor | Hydrostatic delivery system for controlled delivery of agent |
BR0211317A (pt) * | 2001-07-04 | 2004-12-14 | Sun Pharmaceutical Ind Ltd | Sistema para a liberação controlada de uma droga por meio de retenção gástrica |
JP2005501097A (ja) * | 2001-08-16 | 2005-01-13 | ザ ステイト オブ オレゴン アクティング バイ アンド スルー ザ ステイト ボード オブ ハイアー エデュケイション、 オン ビハーフ オブ オレゴン ステイト ユニバーシティー | 膨張可能な胃内滞留装置 |
WO2003017981A1 (en) * | 2001-08-29 | 2003-03-06 | Ranbaxy Laboratories Limited | Controlled release formulation of clarithromycin or tinidazol |
CA2466032A1 (en) * | 2001-10-29 | 2003-05-08 | Laure Patricia Ouadji Njiki | Methods and dosage forms for improving the bioavailability of therapeutic agents |
PL374280A1 (en) * | 2001-11-13 | 2005-10-03 | Yamanouchi Pharma Technologies, Inc. | Soluble drug extended release system |
US8192755B2 (en) | 2001-11-19 | 2012-06-05 | Lupin Limited | Pharmaceutical composition for controlled release of a beta-lactam antibiotic |
MXPA04010436A (es) * | 2002-04-23 | 2005-05-27 | Lupin Ltd | Composiciones de accion a largo plazo que comprenden zidovudina y lamivudina. |
WO2005018613A1 (de) * | 2003-08-26 | 2005-03-03 | Mandapro Ag | Pellets für die orale applikation von pharmazeutischen wirkstoffen |
DE102004042139B4 (de) * | 2004-08-31 | 2009-06-10 | Aristocon Verwaltungs- Gmbh | Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit |
GB0501810D0 (en) * | 2005-01-28 | 2005-03-09 | Pharmakodex Ltd | Chemotherapeutic formulations |
EP1912628A2 (en) * | 2005-06-29 | 2008-04-23 | Panacea Biotec Ltd. | Pharmaceutical sustained release compositions and processes thereof |
DE602005007205D1 (de) * | 2005-07-19 | 2008-07-10 | Ethypharm Sa | Gastroretentive Zusammensetzungen und Verfahren zur Herstellung |
GB0515492D0 (en) * | 2005-07-28 | 2005-08-31 | Reckitt Benckiser Healthcare | Improvements in or relating to compositions,articles and methods |
KR20080076382A (ko) * | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
ZA200903854B (en) * | 2008-06-19 | 2011-02-23 | Univ Of The Witwatesrand Johannesburg | A gastroretentive pharmaceutical dosage form |
JP2012500230A (ja) | 2008-08-18 | 2012-01-05 | 北京天衡▲薬▼物研究院 | 胃内滞留薬物放出システム及びその製造方法と使用 |
WO2011125075A2 (en) | 2010-04-08 | 2011-10-13 | Fdc Limited | A novel gastroretentive delivery of macrolide |
EP2415460A1 (de) * | 2010-08-03 | 2012-02-08 | ratiopharm GmbH | Orale Darreichungsform von Pregabalin |
TWI705814B (zh) * | 2014-06-20 | 2020-10-01 | 美商梅琳塔有限責任公司 | 醫藥組成物及其用途 |
US11504324B2 (en) | 2014-11-19 | 2022-11-22 | DuPont Nutrition USA, Inc. | Nanosuspension formulation |
US10987311B2 (en) | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
US10588863B2 (en) | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
CN110996922A (zh) | 2017-06-16 | 2020-04-10 | 卡希夫生物科学有限责任公司 | 用于持续药物递送的胃滞留剂型 |
US11229606B2 (en) | 2018-06-18 | 2022-01-25 | Amneal Complex Products Research Llc | Extended release compositions comprising pyridostigmine |
JP7034343B2 (ja) | 2018-06-27 | 2022-03-11 | アムニール コンプレックス プロダクツ リサーチ エルエルシー | 自己調節性の浸透性胃保持性薬物送達システム |
CN110448535A (zh) * | 2019-09-04 | 2019-11-15 | 湖南宇山玉月农业科技有限公司 | 一种裂褶菌素胃漂浮片 |
CN111116794A (zh) * | 2019-12-20 | 2020-05-08 | 蚌埠市鑫晟新材料科技有限公司 | 一种中性造纸用聚合材料的制备方法 |
CN115715765A (zh) * | 2021-08-24 | 2023-02-28 | 江苏万邦生化医药集团有限责任公司 | 一种悬浮片剂 |
CN113768898A (zh) * | 2021-09-14 | 2021-12-10 | 江苏万邦生化医药集团有限责任公司 | 悬浮的胶囊片 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0798742B2 (ja) * | 1986-07-03 | 1995-10-25 | ゼリア新薬工業株式会社 | 徐放性製剤組成物 |
US5096714A (en) * | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
JPH0624959A (ja) * | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
-
1999
- 1999-01-19 DK DK99900106T patent/DK1107741T3/da active
- 1999-01-19 TR TR2001/00731T patent/TR200100731T2/xx unknown
- 1999-01-19 JP JP2000569782A patent/JP2002524494A/ja active Pending
- 1999-01-19 CU CU20010067A patent/CU23040A3/es unknown
- 1999-01-19 MX MXPA01002634A patent/MXPA01002634A/es not_active Application Discontinuation
- 1999-01-19 ID IDW20010594A patent/ID29843A/id unknown
- 1999-01-19 CA CA002343760A patent/CA2343760A1/en not_active Abandoned
- 1999-01-19 DE DE69909801T patent/DE69909801T2/de not_active Expired - Fee Related
- 1999-01-19 EA EA200300847A patent/EA005767B1/ru not_active IP Right Cessation
- 1999-01-19 UA UA2001031727A patent/UA73287C2/uk unknown
- 1999-01-19 AP APAP/P/2001/002098A patent/AP1659A/en active
- 1999-01-19 SI SI9930376T patent/SI1107741T1/xx unknown
- 1999-01-19 IL IL14197799A patent/IL141977A0/xx unknown
- 1999-01-19 ES ES99900106T patent/ES2204098T3/es not_active Expired - Lifetime
- 1999-01-19 EP EP99900106A patent/EP1107741B1/en not_active Expired - Lifetime
- 1999-01-19 PL PL99346798A patent/PL346798A1/xx unknown
- 1999-01-19 EP EP02023169A patent/EP1281397A1/en not_active Withdrawn
- 1999-01-19 NZ NZ523747A patent/NZ523747A/en unknown
- 1999-01-19 OA OA1200100064A patent/OA11652A/en unknown
- 1999-01-19 GE GEAP19995796A patent/GEP20043216B/en unknown
- 1999-01-19 BR BR9913696-1A patent/BR9913696A/pt not_active IP Right Cessation
- 1999-01-19 EA EA200100346A patent/EA004443B1/ru not_active IP Right Cessation
- 1999-01-19 PT PT99900106T patent/PT1107741E/pt unknown
- 1999-01-19 HU HU0103632A patent/HUP0103632A3/hu unknown
- 1999-01-19 AU AU17794/99A patent/AU758324B2/en not_active Ceased
- 1999-01-19 WO PCT/IB1999/000078 patent/WO2000015198A1/en not_active Application Discontinuation
- 1999-01-19 SK SK347-2001A patent/SK285478B6/sk unknown
- 1999-01-19 CZ CZ2001901A patent/CZ2001901A3/cs unknown
- 1999-01-19 CN CNB998129887A patent/CN1186013C/zh not_active Expired - Fee Related
- 1999-01-19 EE EEP200100153A patent/EE200100153A/xx unknown
- 1999-01-19 AT AT99900106T patent/ATE245414T1/de not_active IP Right Cessation
- 1999-01-19 NZ NZ510487A patent/NZ510487A/xx unknown
- 1999-09-10 ZA ZA9905839A patent/ZA995839B/xx unknown
- 1999-09-13 SV SV1999000152A patent/SV1999000152A/es not_active Application Discontinuation
- 1999-09-13 PE PE1999000924A patent/PE20001058A1/es not_active Application Discontinuation
- 1999-09-13 MY MYPI99003949A patent/MY127952A/en unknown
- 1999-09-14 CO CO99058020A patent/CO5130022A1/es unknown
- 1999-09-14 UY UY25710A patent/UY25710A1/es unknown
- 1999-09-17 AR ARP990104682A patent/AR022672A1/es not_active Application Discontinuation
-
2001
- 2001-03-12 IS IS5885A patent/IS5885A/is unknown
- 2001-03-13 BG BG105339A patent/BG105339A/xx unknown
- 2001-03-13 HR HR20010187A patent/HRP20010187B1/xx not_active IP Right Cessation
- 2001-03-13 NO NO20011276A patent/NO20011276L/no unknown
- 2001-12-11 HK HK01108695A patent/HK1037967A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR022672A1 (es) | Una composicion farmaceutica en forma de tabletas o capsulas que constituyen un metodo de administracion oral de una droga | |
YU19501A (sh) | Sistem za kontrolisano davanje lekova oralnim putem koji obezbeđuje vremensku i prostornu kontrolu | |
KR100890180B1 (ko) | 경구투여제 및 경구투여제 유지체 | |
IL143375A0 (en) | Sustained release matrix systems for highly soluble drugs | |
RU94032150A (ru) | Лекарственное средство с замедленным высвобождением активно-действующего вещества | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
DE60310039D1 (de) | Pharmazeutische tablette | |
KR20060135052A (ko) | 경구투여제 | |
EP0966966A3 (en) | Nefazodone dosage form | |
MY144021A (en) | Pharmaceutical delivery system | |
JP2007254340A (ja) | 経口投与剤 | |
CN113476421A (zh) | 一种非布司他的控释组合物及其制备方法 | |
HN2001000038A (es) | Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina | |
ES2194618T1 (es) | Composicion oralmente desintegrable que comprende mirtazapina. | |
RU2005105302A (ru) | Композиция бицифадина | |
ECSP993138A (es) | Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial | |
WO2016137266A2 (ko) | 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물 | |
ES2572180T3 (es) | Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada | |
JP4527942B2 (ja) | 粘膜粘着性活性物質賦形剤の放出用の胃液耐性デバイス、およびこの胃液耐性デバイスの製造方法 | |
AR018041A1 (es) | Formulaciones de tiagabina de liberacion prolongada, encapsulada y en comprimidos | |
DE60219965D1 (de) | Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine | |
TH50543A3 (th) | ระบบการนำส่งยาที่ควบคุมได้สำหรับให้ทางปากซึ่งให้การควบคุมเกี่ยวกับเวลาและบริเวณ | |
UY28579A1 (es) | Formulaciones farmacéuticas transdermicas | |
NZ513416A (en) | Pill dough formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |